

Astellas Clinical Transparency
Information Regarding Results Posting for a Transitioned Trial

EudraCT ID: 2018-002301-61

EU CTID: 2024-512469-15

Protocol Title: A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Sponsor: Astellas Pharma Global Development, Inc.

The results for this trial are posted on Clinical Trials Information System (CTIS), as the trial has officially transitioned to this platform.